This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing National Vision (EYE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 22.22% and 6.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q3 Earnings Top Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.
National Vision (EYE) Q3 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 87.50% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy National Vision (EYE) Ahead of Earnings?
by Zacks Equity Research
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Earnings Preview: Verano Holdings Corp. (VRNOF) Q3 Earnings Expected to Decline
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -15.15% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.
National Vision (EYE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.
AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.
Why National Vision (EYE) Could Beat Earnings Estimates Again
by Zacks Equity Research
National Vision (EYE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alcon (ALC) Clareon Suite to Get a Boost With Product Launch
by Zacks Equity Research
With the latest launch of Clareon Toric, Alcon's (ALC) Clareon Collection of IOLs is complete in the United States.
National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut
by Zacks Equity Research
National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.
Company News for Aug 12, 2022
by Zacks Equity Research
Companies in The News Are: HBI,DDS,SIX,EYE
National Vision (EYE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 162.50% and 1.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why National Vision (EYE) Might Surprise This Earnings Season
by Zacks Equity Research
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Verano Holdings Corp. (VRNOF) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is VAALCO (EGY) Poised for a Robust Q2 Earnings Performance?
by Zacks Equity Research
While higher oil prices are likely to have boosted VAALCO Energy's (EGY) profit levels in the second quarter, escalation in costs might have played spoilsport.
National Vision (EYE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Higher Margins Boost HF Sinclair (DINO) Q2 Earnings?
by Zacks Equity Research
While higher refining margins and throughput are likely to have boosted HF Sinclair's (DINO) profit levels in the second quarter, escalation in costs might have played spoilsport.
NanoString (NSTG) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
NanoString (NSTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.